Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment.
|
| Abstract |
Splenectomy is considered as one of the first-line treatments for symptomatic patients with splenic marginal zone lymphoma (SMZL). Between 1997 and 2012, 100 hepatitis C virus-negative patients with SMZL were treated by splenectomy as first-line treatment. At 6 months, all patients but three recovered from all cytopenias. The median lymphocyte count at 6 months and 1 year was 11.51 × 10(9)/L and 6.9 × 10(9)/L, respectively. Median progression-free survival (PFS) was 8.25 years. The 5-year and 10-year overall survival (OS) rates were 84% and 67%, respectively. Histological transformation occurred in 11% of patients, and was the only parameter significantly associated with a shorter time to progression (p = 0.0001). Significant prognostic factors for OS were age (p = 0.0356) and histological transformation (p = 0.0312). In this large retrospective cohort, we confirmed that splenectomy as first-line treatment in patients with SMZL corrected cytopenias and lymphocytosis within the first year and was associated with a good PFS.
|
|---|---|
| Authors | Julien Lenglet, Catherine Traullé, Nicolas Mounier, Claire Benet, Nicolas Munoz-Bongrand, Sandy Amorin, Maria-Elena Noguera, Alexandra Traverse-Glehen, Martine Ffrench, Lucile Baseggio, Pascale Felman, Evelyne Callet-Bauchu, Pauline Brice, Françoise Berger, Gilles Salles, Josette Brière, Bertrand Coiffier, Catherine Thieblemont |
| Journal | Leukemia & lymphoma (Leuk Lymphoma) Vol. 55 Issue 8 Pg. 1854-60 (Aug 2014) ISSN: 1029-2403 [Electronic] United States |
| PMID | 24206091 (Publication Type: Journal Article) |
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!